Literature DB >> 23831889

[Tumor and transplantation].

M Guba1, J Andrassy, M Angele, C Bruns.   

Abstract

Tumor treatment and transplantation-associated with unavoidable mandatory immunosuppression-appear to be unreconcilable opposites. The clinical reality shows, however, that transplantation in many early stage primary tumors is the most effective treatment. The essential immunosuppression after transplantation can however promote tumor recurrence. Immunosuppression also leads to a significant increased rate of de novo tumors-in all organ transplant recipients. However, not all immunosuppressant drugs have the same effect on tumors. In experimental and clinical settings, the class of mTOR inhibitors has a clear antitumoral effect and is recommended as the immunosuppression treatment of choice in patients with increased tumor risk. The purpose of this review is to provide the reader with the scientific background regarding the clinical problem of tumors and transplantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23831889     DOI: 10.1007/s00104-012-2426-3

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  69 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

2.  Posttransplantation de novo tumors in liver allograft recipients.

Authors:  I Penn
Journal:  Liver Transpl Surg       Date:  1996-01

3.  Effect of cyclosporin A on apoptosis and expression of p53 and bcl-2 proteins in the gingiva of renal transplant patients.

Authors:  Sule Bulut; B Handan Ozdemir; Emine Elif Alaaddinoĝlu; Füsun Bahar Oduncuoĝlu; Omer Engin Bulut; Beyhan Demirhan
Journal:  J Periodontol       Date:  2005-05       Impact factor: 6.993

4.  Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.

Authors:  Marco Vivarelli; Alessandro Dazzi; Matteo Zanello; Alessandro Cucchetti; Matteo Cescon; Matteo Ravaioli; Massimo Del Gaudio; Augusto Lauro; Gian Luca Grazi; Antonio Daniele Pinna
Journal:  Transplantation       Date:  2010-01-27       Impact factor: 4.939

5.  Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation.

Authors:  Daniel B Yarosh; Arely V Pena; Stephanie L Nay; Matthew T Canning; David A Brown
Journal:  J Invest Dermatol       Date:  2005-11       Impact factor: 8.551

6.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

7.  Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Authors:  Jens Rosenau; Matthias J Bahr; Reinhard von Wasielewski; Michael Mengel; Hartmut H J Schmidt; Björn Nashan; Hauke Lang; Jürgen Klempnauer; Michael P Manns; Klaus H W Boeker
Journal:  Transplantation       Date:  2002-02-15       Impact factor: 4.939

8.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

9.  Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.

Authors:  S Huber; C J Bruns; G Schmid; P C Hermann; C Conrad; H Niess; R Huss; C Graeb; K-W Jauch; C Heeschen; M Guba
Journal:  Kidney Int       Date:  2007-02-14       Impact factor: 10.612

10.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.